Floatz Rating
B62/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04197713CT.gov Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study | — | Active Not Recruiting | — | — | — |
NCT03253679CT.gov AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification | — | Completed | — | — | — |
NCT04439227CT.gov Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) | — | Active Not Recruiting | — | — | — |
NCT02465060CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
NCT02511795CT.gov AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | — | Completed | — | — | — |
NCT02095132CT.gov Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Refractory Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adavosertib (this asset) | National Cancer Institute (NCI) | P2 | B · 62 |
| Catequentinib | Nanfang Hospital, Southern Medical University | P3 | BB |
| Irinotecan | M.D. Anderson Cancer Center | P2 | BB |
| Durvalumab | OHSU Knight Cancer Institute | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Nivolumab | CatalYm GmbH | P2 | BB |
| Sugemalimab | Second Affiliated Hospital of Soochow University | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Gm-Csf | Second Affiliated Hospital of Soochow University | P2 | B |
+42 more in the Refractory Malignant Neoplasm cohort
Other indications for Adavosertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Female Reproductive Organ Cancer | — | P2 | B · 59 |
| Exocrine Pancreatic Carcinoma | — | P2 | B · 59 |
| Acute Myeloid Leukemia | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adavosertib in Refractory Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adavosertib-refractory-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →